Skip to main content
OpenTrials
Completed

NCT Number: NCT02327000

A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.

GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption by Extending the Absorption Site.

To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

About this study

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.

The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.

At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.

This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 19~45 years old, Healthy Adult Male Subject
  • 17.5~30.5kg/m2(BMI) and ≥ 40kg(Body Weight)

Exclusion criteria

  • SBP ≥ 140mmHg or DBP ≥ 90mmHg

Treatment and study plan

Pregabalin 150mg

Drug

GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)

Other names: GLA5PR GLARS-NF1 tablet 150mg

Pregabalin 300mg

Drug

GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)

Other names: GLA5PR GLARS-NF1 tablet 300mg

Primary outcomes

  1. AUClast

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

  2. Cmax

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

Secondary outcomes

  1. AUCinf

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

  2. Tmax

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

  3. t1/2

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

  4. CL/F

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

  5. Vd/F

    Time frame: 36hrs

    Pharmacokinetic of Pregabalin

Sponsors and collaborators

Lead sponsor

GL Pharm Tech Corporation

Industry

Registry information

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Dec 30, 2014
Registry last updated
Dec 30, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.